Bausch + Lomb Q1 Earnings Forecast Boosted by HC Wainwright

Key Points

• HC Wainwright raised its Q1 2027 EPS forecast for Bausch + Lomb to $0.16 from $0.12, while maintaining a Neutral rating and a $22 price target. It also forecast $0.29 EPS for Q2 2027.
• Bausch + Lomb’s latest results exceeded expectations, with EPS of $0.34 versus the $0.21 consensus and revenue of $1.38 billion. Revenue increased 7.3% year over year.
• Analyst sentiment remains mixed: the stock has an average Hold rating and a consensus price target of $20.83, while insiders have sold approximately $3.49 million of shares over the past 90 days.

Bausch + Lomb Corporation (NYSE:BLCO - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2027 earnings per share (EPS) estimates for shares of Bausch + Lomb in a report released on Monday, November 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.16 per share for the quarter, up from their previous forecast of $0.12. HC Wainwright currently has a "Neutral" rating and a $22.00 price target on the stock. The consensus estimate for Bausch + Lomb's current full-year earnings is $0.94 per share. HC Wainwright also issued estimates for Bausch + Lomb's Q2 2027 earnings at $0.29 EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.13. The firm had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.02% and a negative net margin of 2.05%. Bausch + Lomb's revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.18 EPS.

Several other equities analysts also recently issued reports on the stock. Royal Bank Of Canada upped their price objective on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company an "outperform" rating in a research note on Thursday, October 29th. Barclays raised shares of Bausch + Lomb to a "strong-buy" rating in a research note on Wednesday, October 7th. Wall Street Zen upgraded Bausch + Lomb from a "buy" rating to a "strong-buy" rating in a report on Saturday. UBS Group started coverage on Bausch + Lomb in a research note on Thursday, July 30th. They set a "buy" rating and a $21.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $20.00 price target on shares of Bausch + Lomb in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $20.83.

Bausch + Lomb Price Performance

Bausch + Lomb stock opened at $20.07 on Tuesday. Bausch + Lomb has a 12-month low of $14.44 and a 12-month high of $21.36. The stock has a market capitalization of $7.17 billion, a P/E ratio of -64.76, a P/E/G ratio of 0.64 and a beta of 0.56. The firm's 50-day moving average is $17.41 and its two-hundred day moving average is $16.70. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02.

Insiders Place Their Bets

In other news, CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $20.48, for a total value of $2,294,067.20. Following the transaction, the chief accounting officer directly owned 45,831 shares of the company's stock, valued at $938,618.88. The trade was a 70.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Eschenbach Andrew C. Von sold 6,059 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $16.58, for a total value of $100,458.22. Following the sale, the director owned 63,733 shares of the company's stock, valued at $1,056,693.14. The trade was a 8.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 183,474 shares of company stock valued at $3,488,437. Insiders own 1.45% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BLCO. Engineers Gate Manager LP acquired a new stake in Bausch + Lomb in the 2nd quarter valued at $1,479,000. Beach Point Capital Management LP purchased a new position in Bausch + Lomb in the third quarter valued at about $5,882,000. Whitebox Advisors LLC raised its position in Bausch + Lomb by 15.8% in the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company's stock valued at $17,519,000 after purchasing an additional 150,641 shares during the period. Sei Investments Co. lifted its stake in shares of Bausch + Lomb by 100.0% during the first quarter. Sei Investments Co. now owns 139,266 shares of the company's stock worth $2,214,000 after purchasing an additional 69,633 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new position in shares of Bausch + Lomb during the third quarter worth about $670,000. Hedge funds and other institutional investors own 11.07% of the company's stock.

More Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Strong-buy and momentum rankings: Zacks added BLCO to its Rank #1 (Strong Buy) lists for both momentum and overall stock selection. Zacks also identified the company as a potential long-term value stock, which may attract growth and value-oriented investors. Best Momentum Stock to Buy for November 2nd Why Bausch + Lomb Is a Top Value Stock
• Positive Sentiment: Higher consensus valuation: The consensus price target reportedly increased 10.44% to $21.92, suggesting analysts see additional upside from recent trading levels. Bausch + Lomb Consensus Price Target Raised
• Positive Sentiment: Operating momentum: Highlights from BLCO’s third-quarter earnings call emphasized strong growth. The company previously reported revenue growth of 7.3% year over year and earnings that exceeded analyst expectations, supporting the bullish case. Bausch + Lomb Earnings Call Highlights Strong Growth
• Neutral Sentiment: Mixed analyst signal: HC Wainwright raised its price target to $22 from $21 but downgraded BLCO from Buy to Neutral, indicating improved valuation expectations but less conviction that the stock will materially outperform. HC Wainwright Downgrades Bausch + Lomb
• Negative Sentiment: Insider selling: Chief Accounting Officer Frederick Munsch sold 112,015 shares worth approximately $2.29 million, reducing his holdings by about 71%. While insider sales can be routine, the transaction may concern investors because of its size.

About Bausch + Lomb

Bausch + Lomb Corporation NYSE: BLCO is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.